Statistics in Biopharmaceutical Research
Leading citation impact metric from Clarivate Journal Citation Reports
11 papers with at least that number of citations each
State Council for Professorship (HĐGSNN) Scoring
Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)
HĐGSNN Score History
By article publication year| Year | Max Score | Evaluation Details | Source |
|---|---|---|---|
| 2026 | 1.50đ | WoS Q2(IF: 1.6) | 🔵 Computed |
| 2025 | 1.50đ | WoS Q2(IF: 1.3) | 🔵 Computed |
| 2024 | 1.50đ | WoS Q2(IF: 1.5) | 🔵 Computed |
| 2023 | 1.50đ | WoS Q2(IF: 1.8) | 🔵 Computed |
| 2022 | 1.50đ | WoS Q2(IF: 1.586) | 🔵 Computed |
| 2021 | 1.50đ | WoS Q2(IF: 1.452) | 🔵 Computed |
| 2020 | 1.50đ | WoS Q2(IF: 0.709) | 🔵 Computed |
| 2019 | 1.50đ | WoS Q2(IF: 0.92) | 🔵 Computed |
| 2018 | 1.50đ | WoS Q2(IF: 0.826) | 🔵 Computed |
Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.
Aims & Scope
Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems. Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application). The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review. Authors can choose to publish gold open access in this journal.
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Measures cumulative publication volume and citation impact.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
| Category | Index | Rank | Quartile |
|---|---|---|---|
MATHEMATICAL & COMPUTATIONAL BIOLOGY | JCRSCIE | 50/67 | Q3 |
STATISTICS & PROBABILITY | JCRSCIE | 62/170 | Q2 |
MATHEMATICAL & COMPUTATIONAL BIOLOGY | JCISCIE | 41/67 | Q3 |
STATISTICS & PROBABILITY | JCISCIE | 80/170 | Q2 |
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
| Year | Impact Factor | Articles / Year | Total Citations |
|---|---|---|---|
| 2026 | — | 58 | 7 |
| 2025 | 1.3 | 72 | 50 |
| 2024 | 1.5 | 52 | 147 |
| 2023 | 1.8 | 73 | 298 |
| 2022 | 1.586 | 60 | 306 |
| 2021 | 1.452 | 81 | 653 |
| 2020 | 0.709 | 94 | 658 |
| 2019 | 0.92 | 78 | 797 |
| 2018 | 0.826 | 34 | 383 |
| 2017 | — | 43 | 365 |
| 2016 | — | 61 | 695 |
| 2015 | — | 50 | 492 |
Journal Metrics & Citation Visualizations
Impact Factor Trend (2018–2024)
Clarivate IF trend for Statistics in Biopharmaceutical Research
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics